Primary focal hyperhidrosis — pathological sweating beyond thermoregulatory need — affects an estimated 2.8% of the population and causes significant social and occupational impairment.1 Botulinum toxin type A (BTX-A) is now the most effective minimally invasive treatment available, with TGA approval for axillary hyperhidrosis and a robust evidence base extending to palmar and plantar sites.
What Is Hyperhidrosis?
Hyperhidrosis is defined as sweating that exceeds what is physiologically necessary to maintain thermal homeostasis. Primary focal hyperhidrosis — the most common form — is not secondary to any systemic condition; it arises from hyperactivation of the sympathetic cholinergic innervation of eccrine sweat glands.2 The axillae are affected in approximately 50% of cases, with the palms, soles, and craniofacial region also commonly involved.1
The Hyperhidrosis Disease Severity Scale (HDSS) is the validated patient-reported instrument most widely used in clinical trials and practice to grade symptom burden from 1 (tolerable sweating) to 4 (intolerable sweating that never stops).3 Most patients presenting for BTX-A treatment score 3 or 4.
Sweating is controlled by the sympathetic nervous system but uses acetylcholine — not noradrenaline — as its neurotransmitter. This is why botulinum toxin, which blocks acetylcholine release, is so effective at eccrine gland suppression.
How Botulinum Toxin Works in Hyperhidrosis
Eccrine sweat glands are innervated by post-ganglionic sympathetic fibres that are, unusually, cholinergic. Acetylcholine binds muscarinic M3 receptors on the secretory coil of the gland to stimulate sweat production.2 BTX-A cleaves SNAP-25 at the presynaptic terminal, blocking acetylcholine vesicle docking and halting secretory stimulation.4 The effect is localised to the injection site and reversible as new axonal sprouting restores neuromuscular and neuroglandular transmission over months.
Critically, this mechanism is independent of the cosmetic mechanism in facial muscles — the target here is not striated muscle but glandular secretomotor innervation. This distinction has important implications for dosing: the doses required for hyperhidrosis are substantially higher than those used in facial aesthetics, yet systemic effects remain minimal owing to the highly localised delivery.4
Efficacy — What the Evidence Shows
The axillary hyperhidrosis evidence base is the most mature. A pivotal multicentre randomised controlled trial by Naumann and Lowe (2001) randomised 320 patients with severe primary axillary hyperhidrosis to BTX-A 50 U per axilla or placebo.5 At four weeks, 93.8% of the BTX-A group achieved at least a 50% reduction in sweating versus 35.9% in the placebo arm. Mean duration of effect was 7.5 months. A subsequent follow-up study confirmed durable efficacy and tolerability across repeated treatment cycles over 16 months.6
Axillae
Highest evidence tier. RCT data shows 93–94% response rate with 50 U BTX-A per axilla. Mean duration 6–9 months.5,6
Palms
Highly effective but more painful to treat. Doses of 100–150 U per palm required. Duration typically 4–6 months.7
Soles
Effective but technically demanding and painful without nerve block. 100–200 U per sole. Less frequently treated than axillae or palms.8
Craniofacial
Evidence is case series level. Gustatory sweating (Frey syndrome) responds particularly well due to localised parasympathetic aetiology.9
For palmar hyperhidrosis, a systematic review by Lecouflet et al. found that BTX-A produced significant sweat reduction in all included studies, with HDSS scores improving by at least 2 points in the majority of patients.7 Pain at the time of injection is the primary limiting factor for palmar treatment; median nerve or wrist blocks using local anaesthetic are commonly employed in clinical practice to improve tolerability.
Injection Technique — Axillae
The standard approach to axillary hyperhidrosis involves a Minor's starch-iodine test to delineate the active sweating zone, followed by intradermal injections on a 1–1.5 cm grid pattern across the marked area.3 The toxin is delivered intradermally — not subcutaneously — to ensure proximity to the eccrine gland secretory coil. Superficial placement produces a characteristic small bleb at each injection point.
Standard Axillary Protocol
- Starch-iodine test to map the hyperhidrotic zone (optional but recommended)
- 50 units BTX-A per axilla (Botox); reconstituted to 4 U per 0.1 mL
- Grid spacing: 1.0–1.5 cm across the marked zone
- Injection depth: intradermal (2–3 mm), bevel up, raising a small wheal
- Ice or topical anaesthetic applied 30–45 minutes prior for comfort
- Onset: 2–4 days; full effect by 2 weeks
Duration and Re-treatment
Duration of effect varies by anatomical site and individual factors including metabolic rate, body temperature regulation demands, and treatment history. Axillary results typically last 6–9 months; palmar and plantar results are generally shorter at 4–6 months, partly due to higher mechanical activity in these regions stimulating faster axonal regeneration.6
Repeated treatment cycles do not appear to produce tachyphylaxis or meaningful immunogenicity at the doses used for hyperhidrosis. Long-term follow-up data from the Naumann and Lowe cohort demonstrated consistent efficacy across eight treatment sessions over four years, with no significant attenuation of effect.6
Unlike facial botulinum toxin where re-treatment intervals of 3–4 months are standard, hyperhidrosis patients frequently achieve 6–9 months of relief per axillary treatment — making the annual treatment burden considerably lower than many patients expect.
Safety Profile
BTX-A for hyperhidrosis has an excellent safety record in the peer-reviewed literature. Adverse effects at the axillary site are predominantly mild and transient: bruising, localised tenderness, and short-lived compensatory sweating at untreated sites (most commonly the trunk) occurring in approximately 5% of patients.5
Palmar treatment carries a small risk of transient intrinsic hand muscle weakness if the toxin reaches the underlying thenar or hypothenar musculature — a complication that resolves fully within weeks but warrants dose conservatism on first treatment, particularly in patients who perform fine motor tasks professionally.7
Systemic effects — generalised weakness, dysphagia, diplopia — are not reported at the doses used for hyperhidrosis in properly conducted injections. The theoretical risk of systemic spread is negligible when intradermal delivery technique is used correctly.4
Common (>5%)
Injection site discomfort, minor bruising, transient erythema at injection points.
Uncommon (1–5%)
Compensatory sweating at distant sites (trunk, groin). Self-limiting and rarely clinically significant.
Rare (<1%)
Transient hand weakness (palmar injections only). Full resolution expected within 4–6 weeks.
Not Reported
Systemic toxicity, immunoresistance, or permanent effects at therapeutic doses used in hyperhidrosis.
Patient Selection
BTX-A is appropriate as second-line therapy after topical aluminium chloride has proven inadequate or intolerable — which is the case for the majority of patients with HDSS score 3–4.3 It is particularly suitable for patients who have failed or declined systemic therapy (glycopyrrolate, oxybutynin) or who are not candidates for surgical sympathectomy.
Contraindications are those common to all BTX-A use: known hypersensitivity to botulinum toxin or formulation excipients, pregnancy, breastfeeding, and concurrent aminoglycoside therapy. Neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton syndrome) are absolute contraindications.4
References
- Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51(2):241–248.
- Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol. 2009;61(2):242–246.
- Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–286.
- Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology and toxicology. Pharmacol Rev. 2017;69(2):200–235.
- Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323(7313):596–599.
- Naumann MK, Lowe NJ, Kumar CR, Hamm H; Hyperhidrosis Clinical Investigators Group. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol. 2003;139(6):731–736.
- Lecouflet M, Leux C, Fenot M, Célerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients. J Am Acad Dermatol. 2013;69(6):960–964.
- Campanati A, Penna L, Guzzo T, et al. Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther. 2003;25(1):298–308.
- de Bree R, Acosta ST, Stokkel MP, Levendag PC, Balm AJ. Towards a rational treatment of Frey syndrome. Head Neck. 2007;29(8):773–778.